Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to unlock secrets of alcoholic liver disease

NCT ID NCT04106518

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is observing heavy drinkers with jaundice to learn more about alcoholic hepatitis, a serious liver condition. Researchers will track survival and liver function over 12 months, and collect genetic samples to better understand the disease. The goal is to improve diagnosis and knowledge, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could improve how doctors diagnose and predict outcomes for alcoholic hepatitis, and point toward new treatment targets.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly lead to a cure or treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 447 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2019

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients admitted to jaundice will receive a liver biopsy in accordance with the usual management for diagnosis of alcoholic hepatitis, according to the recommendations of the European Association of Liver Diseases (EASL).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For SAH group: * Alcohol consumption : * On average\> 40 g / day for women and 50 g / day for men * Duration:\> 5 years * Recent jaundice episode (less than 3 months) * Bilirubin\> 50 mg / l (85μmol / l) For NSAH group: \- Alcohol consumption : * On average\> 40 g / day for women and 50 g / day for men * Duration:\> 5 years For cirrhosis (control) group: * Alcohol consumption : * On average\> 40 g / day for women and 50 g / day for men * Duration:\> 5 years * Unambiguous presence of cirrhosis criteria, including: * clinical signs (ascites, stellar angiomas ...) and / or * radiological signs (scanner or MRI: signs of hepatic dysmorphism and / or portal hypertension) and / or * biological signs (increased INR, thrombocytopenia) and / or * endoscopic signs (oesophageal / gastric varices) Exclusion Criteria: For NAH and NSAH groups: * Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease) * Presence of hepatocellular carcinoma * HIV infection For cirrhosis (control) group: * History established / suggestive of HAA (Clinical, biological and / or histological criteria) in particular absence of jaundice episode * Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease) * Presence of hepatocellular carcinoma * HIV infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcoholic cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcoholic hepatitis alcoholic liver cirrhosis alcoholic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcoholic cirrhosis Alcoholic liver disease Severe alcoholic hepatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Association Hopital Saint Joseph - Marseille

    RECRUITING

    Marseille, France

  • Centre Hospitalier Universitaire

    RECRUITING

    Caen, France

  • Chr Angers

    RECRUITING

    Angers, France

  • Chru Besancon

    RECRUITING

    Besançon, France

  • Chu Montpellier

    RECRUITING

    Montpellier, France

  • Hopital Nord - Chu38 - La Tronche

    RECRUITING

    La Tronche, France

  • Hu Est Parisien Site St Antoine Aphp - Paris 12

    RECRUITING

    Paris, France

  • Hôpital Claude Huriez, CHU

    RECRUITING

    Lille, France

  • Hôpital Jean Verdier, AH-HP

    RECRUITING

    Bondy, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.